Immunovant Inc. reported cash and cash equivalents of approximately $521.9 million as of September 30, 2025, providing financial runway through expected Graves' disease readout in 2027. The company continues development of IMVT-1402, with potentially registrational studies progressing in Graves' disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, difficult-to-treat rheumatoid arthritis, and Sjögren's disease. Results from the open-label portion of the IMVT-1402 trial in difficult-to-treat rheumatoid arthritis and topline results from the proof-of-concept trial in cutaneous lupus erythematosus are expected in 2026. Topline results from potentially registrational trials in three indications are anticipated in 2027. Immunovant expects to share topline results from both Phase 3 thyroid eye disease studies for batoclimab concurrently in the first half of 2026.